RIPGBM

CAS No. 355406-76-7

RIPGBM ( —— )

Catalog No. M14216 CAS No. 355406-76-7

RIPGBM is a cell type-selective, small molecule inducer of apoptosis in GBM cancer stem cells (CSCs) with EC50 of 220 nM (GBM 1 cells).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 29 Get Quote
5MG 47 Get Quote
10MG 80 Get Quote
25MG 177 Get Quote
50MG 318 Get Quote
100MG 530 Get Quote
200MG 678 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    RIPGBM
  • Note
    Research use only, not for human use.
  • Brief Description
    RIPGBM is a cell type-selective, small molecule inducer of apoptosis in GBM cancer stem cells (CSCs) with EC50 of 220 nM (GBM 1 cells).
  • Description
    RIPGBM is a cell type-selective, small molecule inducer of apoptosis in GBM cancer stem cells (CSCs) with EC50 of 220 nM (GBM 1 cells); RIPGBM is converted to an apoptosis-inducing derivative (cRIPGBM/RIPGBM-18) selectively in GBM CSCs; cRIPGBM induces apoptosis in GBM CSCs by interacting with RIPK2; significantly suppress tumor formation in vivo in orthotopic intracranial GBM CSC tumor xenograft mouse model.
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    RIP kinase
  • Recptor
    RIP kinase
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    355406-76-7
  • Formula Weight
    428.46
  • Molecular Formula
    C26H21FN2O3
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CC(=O)N(CC1=CC=C(C=C1)F)C2=C(C(=O)C3=CC=CC=C3C2=O)NCC4=CC=CC=C4
  • Chemical Name
    N-(3-(benzylamino)-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-N-(4-fluorobenzyl)acetamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Lucki NC, et al. Proc Natl Acad Sci U S A. 2019 Mar 7. pii: 201816626. doi: 10.1073/pnas.1816626116.
molnova catalog
related products
  • CSLP43

    CSLP43 (RIPK2 inhibitor CSLP43) is a novel potent, ATP pocket-binding RIPK2 inhibitor with IC50 of 19.9 nM in ADPGlo assay.

  • GSK-583

    A potent, selective and orally bioavailable RIPK2 kinase inhibitor with IC50 of 5 nM and 2 nM for human and rat RIP2, respectively.

  • WEHI-345

    A potent and selective RIPK2 inhibitor with IC50/Kd of 130/46 nM; displays negligible activity (>10 uM) against RIPK1, RIPK4 and RIPK5.